A-101 Vehicle + A-101 (40) Topical Solution + A-101 (32.5) Topical Solution
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Seborrheic Keratosis
Conditions
Seborrheic Keratosis
Trial Timeline
Jun 1, 2014 → Dec 1, 2014
NCT ID
NCT02160626About A-101 Vehicle + A-101 (40) Topical Solution + A-101 (32.5) Topical Solution
A-101 Vehicle + A-101 (40) Topical Solution + A-101 (32.5) Topical Solution is a phase 2 stage product being developed by Aclaris Therapeutics for Seborrheic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02160626. Target conditions include Seborrheic Keratosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02160626 | Phase 2 | Completed |
Competing Products
15 competing products in Seborrheic Keratosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Elidel + Ketoconazole Cream | Novartis | Phase 2 | 52 |
| PF-07038124 + Placebo Ointment | Pfizer | Phase 2 | 51 |
| Ketoconazole | GSK plc | Approved | 84 |
| Azelaic Acid 15% Gel + Inactive 15% gel base | Bayer | Phase 2 | 49 |
| Ruxolitinib 1.5% Cream | Incyte | Phase 2 | 49 |
| Roflumilast Foam 0.3% + Vehicle foam | Arcutis Biotherapeutics | Phase 2 | 47 |
| Roflumilast Foam + Vehicle Foam | Arcutis Biotherapeutics | Phase 3 | 72 |
| ARQ-154 | Arcutis Biotherapeutics | Phase 2 | 47 |
| A-101 Solution | Aclaris Therapeutics | Phase 3 | 69 |
| A-101 Solution | Aclaris Therapeutics | Phase 3 | 69 |
| A-101 Topical Solution | Aclaris Therapeutics | Approved | 77 |
| A-101 | Aclaris Therapeutics | Phase 2 | 44 |
| A-101 Solution | Aclaris Therapeutics | Phase 3 | 69 |
| A-101 | Aclaris Therapeutics | Phase 2 | 44 |
| A-101 25% + A-101 32.5% + A-101 40% + A-101 Vehicle | Aclaris Therapeutics | Phase 1/2 | 33 |